Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/9049
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsironis, L. D.en
dc.contributor.authorKatsouras, C. S.en
dc.contributor.authorLourida, E. S.en
dc.contributor.authorMitsios, J. V.en
dc.contributor.authorGoudevenos, J.en
dc.contributor.authorElisaf, M.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:46:14Z-
dc.date.available2015-11-24T16:46:14Z-
dc.identifier.issn0021-9150-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9049-
dc.rightsDefault Licence-
dc.subjectatherosclerosisen
dc.subjectcoronary artery diseaseen
dc.subjectenzyme (kinetics)en
dc.subjectlipoprotein(a)en
dc.subjectpaf-acetylhydrolaseen
dc.subjectplatelet-activating-factoren
dc.subjectlow-density-lipoproteinen
dc.subjecthuman-plasmaen
dc.subjectoxidative modificationen
dc.subjectin-vitroen
dc.subjectantiphospholipid antibodiesen
dc.subjectstructural identificationen
dc.subjectendothelial-cellsen
dc.subjectprotein-cen
dc.subjectapolipoprotein(a)en
dc.titleReduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery diseaseen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDOI 10.1016/j.atherosclerosis.2004.07.030-
heal.identifier.secondary<Go to ISI>://000225234800026-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0021915004003806/1-s2.0-S0021915004003806-main.pdf?_tid=a37f8be45b5ab8e12b8956a468b51909&acdnat=1333112322_eaeceff5ce2b2544e1f869489e9df414-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2004-
heal.abstractLipoprotein(a) [Lp(a)] may be an independent risk factor for coronary artery disease (CAD). Lp(a) is enriched in platelet activating factor acetylhydrolase (PAF-AH), an enzyme which hydrolyzes and inactivates platelet activating factor (PAF) and oxidized phospholipids that are implicated in atherogenesis. We determined the mass and catalytic properties of the Lp(a)-associated PAF-AH in 28 CAD patients in relation to the LDL-associated enzyme ones. Results were then compared to those of 30 control subjects and 16 unrelated patients with primary hypercholesterolemia (Type IIA dyslipidemia) before and after atorvastatin therapy. The mass, the specific activity and kinetic constants of the Lp(a)-associated PAF-AH were significantly lower in CAD patients compared to those of either controls or hypercholesterolemic patients, a phenomenon not observed for LDL-associated PAF-AH. The enzyme specific activity and kinetic constants were significantly increased after removal of apo(a) from Lp(a) by reductive cleavage, which was not found in the control population, suggesting that the apo(a) moiety of Lp(a) from CAD patients may play an important role in the observed lower catalytic efficiency of PAF-AH. The reduced PAF-AH mass and specific activity on Lp(a) is a feature characteristic of this lipoprotein in CAD patients and may lead to a diminished capability of Lp(a) to degrade proinflammatory phospholipids. The consequences of this phenomenon as regards the pathophysiological role of Lp(a) in atherosclerosis remain to be established.en
heal.publisherElsevier Irelanden
heal.journalNameAtherosclerosisen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Tsironis-2004-Reduced PAF-acetylhy.pdf158.48 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons